Sartorius Stedim Biotech (DIM) Q4 2025 earnings summary

Executive summary

• Achieved and exceeded 2025 guidance with strong profitable growth, driven by recurring consumables and margin expansion, despite FX and US tariff headwinds.

• Growth was supported by both Bioprocess Solutions and Lab Products & Services, with the latter improving in H2 and positive momentum in instruments.

• Healthy cash flow and deleveraging progress, with leverage ratios improving and workforce expansion mainly in production roles.

• Solid foundation laid for 2026, with continued focus on innovation, operational excellence, and financial discipline.

Financial highlights

• Sales revenue increased by 7.6% in constant currencies (9.6% for Sartorius Stedim Biotech), reaching over EUR 3.5 billion; Bioprocess Solutions up 9.5%, Lab Products & Services up 0.2%.

• Underlying EBITDA rose 11.2% to EUR 1.052 billion, margin expanding to 29.7%; Sartorius Stedim Biotech margin at 30.8%.

• Underlying net profit grew 18% to EUR 331 million; reported net profit up 84% to EUR 155 million; Sartorius Stedim Biotech net profit up 51.7% to EUR 266 million.

• Underlying EPS increased 18.1% to EUR 4.78; Sartorius Stedim Biotech EPS up 50.9% to EUR 2.73.

• Operating cash flow was EUR 837 million, free cash flow EUR 390 million; Sartorius Stedim Biotech free cash flow EUR 295 million.

Outlook and guidance

• 2026 group sales revenue growth expected at 5%-9% in constant currencies; Bioprocess Solutions 6%-10%, Lab Products & Services 2%-6%.

• Underlying EBITDA margin projected slightly above 30% for the group, above 32% for Bioprocess Solutions, and slightly below 21% for Lab Products & Services.

• CapEx ratio to remain around prior-year level (12.5%-13.3%); net debt/EBITDA to decrease to slightly above 3x for the group and slightly above 2 for Sartorius Stedim Biotech.

• Guidance reflects ongoing macroeconomic, geopolitical, and industry-specific volatility, with potential additional US tariffs not included.